GENPET

GENPET is an observational study looking at the use of PET scanning in men with a germline DNA Repair genemutation who have developed prostate cancer.

Men with germlineDNA Repair gene (found on the R430 panel in the UK Cancer Genomic National Test Directory) mutations are more susceptible to prostate cancer than men without a mutation.

The aim of the study is to determine if FCH-PET-CT imaging is superior to combined bone scan and MRI of the abdomen & pelvis in detecting the increased incidence of metastasis (nodal/distant outside the pelvis) in men with prostate cancer and who have a germline DNA Repair Gene mutations.

The study is currently open to recruitment at the Royal Marsden Hospital.

Eligibility:

• Patients with a new diagnosis of prostate cancer who carry a germline DNA Repair gene mutation in either BRCA1, BRCA2, MSH2, MSH6, PMS2, CHEK2, PALB2, or ATM, regardless of Gleason score or PSA
• Patients who carry a germline DNA Repair gene mutation in either BRCA1, BRCA2, MSH2, MSH6, PMS2, CHEK2, PALB2, or ATM and who previously underwent radical treatment (surgical or radiotherapy) and are now presenting with biochemical relapse as defined by the EAU guidelines
• Men with prostate cancer and a germline DNA Repair gene mutation in either BRCA1, BRCA2, MSH2, MSH6, PMS2, CHEK2, PALB2, or ATM on active surveillance for at least 6 months, with a PSA doubling time of 6 months or less